Antiemetics for Pediatric Patients

Primary Antiemetic Agents

The American Society of Clinical Oncology recommends pediatric patients receive 5-HT3 receptor antagonists (ondansetron or granisetron) as first-line antiemetics, with dexamethasone added for moderate-to-high emetogenic risk situations, and aprepitant for high-risk chemotherapy regimens 1, 2
Ondansetron is the most extensively studied and recommended first-line antiemetic in pediatric patients across multiple clinical contexts, with a standard dosing of 0.15 mg/kg per dose (maximum 16 mg per dose) IV or IM, and is safe in children as young as 6 months 1, 2
Granisetron represents an equally effective alternative 5-HT3 antagonist with similar safety profile, available as oral tablets, liquid formulation, or transdermal patch, and is particularly useful when ondansetron is contraindicated due to QT prolongation concerns or allergy 1, 3

For high-emetic-risk chemotherapy, a three-drug regimen of 5-HT3 antagonist + dexamethasone + aprepitant is recommended, with the American Society of Clinical Oncology suggesting this combination for cisplatin, ifosfamide, and high-dose cyclophosphamide 1
For moderate-emetic-risk chemotherapy, a two-drug regimen of 5-HT3 antagonist + dexamethasone is recommended, with the American Society of Clinical Oncology suggesting this combination for carboplatin, doxorubicin, and standard-dose cyclophosphamide 1
Ondansetron is recommended for children >4 years with acute gastroenteritis and vomiting to facilitate oral rehydration, with a dosing of 0.15 mg/kg IM (maximum 16 mg) for children ≥6 months, and must be used after ensuring adequate hydration or alongside rehydration efforts 2, 4

Metoclopramide should NOT be used as first-line therapy in pediatric patients due to high incidence of dystonic reactions and extrapyramidal symptoms, and should not be used for multiple consecutive days 2, 4
Prochlorperazine causes extrapyramidal symptoms and sedation, making it problematic for neurological monitoring, and is not recommended as first-line treatment 3

Exercise special caution in children with pre-existing cardiac disease due to potential QT interval prolongation with 5-HT3 antagonists, and obtain baseline ECG if patient has known cardiac disease 2, 4, 3, 1
Monitor electrolytes, particularly potassium and magnesium, as abnormalities increase QT prolongation risk, and ensure adequate hydration before or during ondansetron administration 4, 3
Do not exceed 16 mg single dose maximum in pediatric patients, and use weight-based dosing (0.15 mg/kg) rather than fixed adult doses 2
In severe hepatic impairment, do not exceed 8 mg total daily dose of ondansetron 3